English

Lexeo Therapeutics, Inc.

EDGAR

LXEO Registration statement (S-3) · filed 2026-10-29

23 filing records in this dataset, filed from 2023-09-29 to 2026-10-29. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q4 · USD

Exact inputs and evidence

Revenue: 654000 USD Source
Revenue: 654000 USD Source

Operating cash flow

-16.6 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -54560000 USD Source
Operating Cash Flow: -37934000 USD Source

Free cash flow

-16.7 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -54560000 USD Source
Operating Cash Flow: -37934000 USD Source
Capital Expenditure: 672000 USD Source
Capital Expenditure: 647000 USD Source

Cash and cash equivalents: 92.8 million USD 2026-06-30 Source
Exact value

92834000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 78.6 million shares 2026-06-30 Source
Exact value

78622604 shares

Reported share-count change

45.60% · 24.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

53998492 shares · 2025-06-30· Source
78622604 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-87.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -20283000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -100000000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -79042000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -20196000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -25867000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-88.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -78482000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -48935000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -98561000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -78482000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21144000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38741000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21144000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

331 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 108000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 35000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 42000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 35000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-88.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -78482000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -48935000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -98561000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -78482000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21144000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38741000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21144000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 108000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 35000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 42000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 35000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 1 of 11 periods available· newest 2022-12-31
Operating income: 4 of 11 periods available· newest 2025-12-31
Net income: 4 of 11 periods available· newest 2025-12-31
Operating cash flow: 4 of 11 periods available· newest 2025-12-31
Capital expenditure: 4 of 11 periods available· newest 2025-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 1.67 million

Prior period

−USD 98.33 million

2024-01-01 – 2024-12-31
Current period

−USD 100 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-100000000 − -98333000 = -1667000 USD

-98333000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-100000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Year-over-year change in Net income: -1667000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -100000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/lxeo-20260630.htm#1078012 Filing: 000119312526345724 Input fundies:NetIncome: -98333000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2917980 Filing: 000119312526132085
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 17.41 million

Prior period

−USD 81.15 million

2024-01-01 – 2024-12-31
Current period

−USD 98.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-98561000 − -81151000 = -17410000 USD

-81151000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-98561000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Year-over-year change in Operating cash flow: -17410000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -98561000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2097295 Filing: 000119312526132085 Input fundies:OperatingCashFlow: -81151000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2099209 Filing: 000119312526132085
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-17.5%

Prior period

USD 481,000

2024-01-01 – 2024-12-31
Current period

USD 397,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

397000 − 481000 = -84000 USD

481000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
397000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Year-over-year change in Capital expenditure: -84000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 397000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2104001 Filing: 000119312526132085 Input fundies:CapitalExpenditure: 481000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2105765 Filing: 000119312526132085
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 654,000 100% of revenue
Operating costs Derived USD 61.16 million 9,352% of revenue
Operating income −USD 60.51 million −9,252% of revenue
Tax, interest and other Derived −USD 1.23 million −188% of revenue
Net income −USD 59.28 million −9,064% of revenue

Cash

Operating cash flow −USD 54.56 million −8,343% of revenue
Capital expenditure USD 672,000 103% of revenue
Free cash flow Derived −USD 55.23 million −8,445% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 9,352% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	654000	61163000 Derived	-60509000	-1232000 Derived	-59277000	-55232000 Derived	Source 2022-01-01 – 2022-12-31: 654000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -60509000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -59277000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -54560000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 672000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 654K 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	654000	Revenue: 654000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 654000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -9,252.1% 2022

Net margin -9,063.8% 2022

Free cash flow margin -8,445.3% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-9,252.1%	Operating Income: -60509000 Open source Revenue: 654000 Open source
20222022-12-31	Net margin	-9,063.8%	Net Income: -59277000 Open source Revenue: 654000 Open source
20222022-12-31	Free cash flow margin	-8,445.3%	Revenue: 654000 Open source Operating Cash Flow: -54560000 Open source Capital Expenditure: 672000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -54.6M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-54560000	Operating Cash Flow: -54560000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -55.2M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-55232000	Operating Cash Flow: -54560000 Open source Capital Expenditure: 672000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

25.7% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	25.7%	Total Liabilities: 24997000 Open source Total Assets: 97076000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.58× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	5.58×	Current Assets: 80048000 Open source Current Liabilities: 14349000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2022 2022-01-01 – 2022-12-31	−USD 59.28 million Exact value Exact value: -59277000 USD 2022-01-01 – 2022-12-31: -59277000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexeo Therapeutics, Inc. · 2022-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Net Income: -59277000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59277000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703ds1.htm#2550737 Filing: 000119312524090233 The citation records this snapshot. The page link may show a newer release later.	−USD 54.56 million Exact value Exact value: -54560000 USD 2022-01-01 – 2022-12-31: -54560000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexeo Therapeutics, Inc. · 2022-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Operating Cash Flow: -54560000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54560000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703ds1.htm#2084689 Filing: 000119312524090233 The citation records this snapshot. The page link may show a newer release later.	USD 672,000 Exact value Exact value: 672000 USD 2022-01-01 – 2022-12-31: 672000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexeo Therapeutics, Inc. · 2022-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Capital Expenditure: 672000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 672000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703ds1.htm#2089662 Filing: 000119312524090233 The citation records this snapshot. The page link may show a newer release later.	−USD 55.23 million Calculation and evidence -54560000 − 672000 USD Exact free cash flow: -55232000 USD 2022-01-01 – 2022-12-31: -54560000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 672000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexeo Therapeutics, Inc. · 2022-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Free cash flow: -55232000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54560000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703ds1.htm#2084689 Filing: 000119312524090233 Input fundies:CapitalExpenditure: 672000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312524090233/d759703ds1.htm#2089662 Filing: 000119312524090233 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 66.39 million Exact value Exact value: -66394000 USD 2023-01-01 – 2023-12-31: -66394000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexeo Therapeutics, Inc. · 2023-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Net Income: -66394000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66394000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm#2975709 Filing: 000095017025043486 The citation records this snapshot. The page link may show a newer release later.	−USD 59.5 million Exact value Exact value: -59496000 USD 2023-01-01 – 2023-12-31: -59496000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexeo Therapeutics, Inc. · 2023-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Operating Cash Flow: -59496000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59496000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm#2120317 Filing: 000095017025043486 The citation records this snapshot. The page link may show a newer release later.	USD 115,000 Exact value Exact value: 115000 USD 2023-01-01 – 2023-12-31: 115000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexeo Therapeutics, Inc. · 2023-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Capital Expenditure: 115000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 115000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm#2129982 Filing: 000095017025043486 The citation records this snapshot. The page link may show a newer release later.	−USD 59.61 million Calculation and evidence -59496000 − 115000 USD Exact free cash flow: -59611000 USD 2023-01-01 – 2023-12-31: -59496000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 115000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexeo Therapeutics, Inc. · 2023-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Free cash flow: -59611000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59496000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm#2120317 Filing: 000095017025043486 Input fundies:CapitalExpenditure: 115000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm#2129982 Filing: 000095017025043486 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 98.33 million Exact value Exact value: -98333000 USD 2024-01-01 – 2024-12-31: -98333000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexeo Therapeutics, Inc. · 2024-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Net Income: -98333000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -98333000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2917980 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.	−USD 81.15 million Exact value Exact value: -81151000 USD 2024-01-01 – 2024-12-31: -81151000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexeo Therapeutics, Inc. · 2024-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Operating Cash Flow: -81151000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81151000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2099209 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.	USD 481,000 Exact value Exact value: 481000 USD 2024-01-01 – 2024-12-31: 481000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexeo Therapeutics, Inc. · 2024-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Capital Expenditure: 481000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 481000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2105765 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.	−USD 81.63 million Calculation and evidence -81151000 − 481000 USD Exact free cash flow: -81632000 USD 2024-01-01 – 2024-12-31: -81151000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 481000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexeo Therapeutics, Inc. · 2024-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Free cash flow: -81632000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -81151000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2099209 Filing: 000119312526132085 Input fundies:CapitalExpenditure: 481000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2105765 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 100 million Exact value Exact value: -100000000 USD 2025-01-01 – 2025-12-31: -100000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Net Income: -100000000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -100000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/lxeo-20260630.htm#1078012 Filing: 000119312526345724 The citation records this snapshot. The page link may show a newer release later.	−USD 98.56 million Exact value Exact value: -98561000 USD 2025-01-01 – 2025-12-31: -98561000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Operating Cash Flow: -98561000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -98561000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2097295 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.	USD 397,000 Exact value Exact value: 397000 USD 2025-01-01 – 2025-12-31: 397000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Capital Expenditure: 397000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 397000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2104001 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.	−USD 98.96 million Calculation and evidence -98561000 − 397000 USD Exact free cash flow: -98958000 USD 2025-01-01 – 2025-12-31: -98561000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 397000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lexeo Therapeutics, Inc. · 2025-12-31 Lexeo Therapeutics, Inc. (edgar:1907108) Free cash flow: -98958000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:55:26Z Snapshot: 32b44cd3b0802089dad400ad441e88295d5cb27013738575fcd20228db19afc4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1907108?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -98561000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2097295 Filing: 000119312526132085 Input fundies:CapitalExpenditure: 397000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm#2104001 Filing: 000119312526132085 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

23 filings · 845 latest values · 845 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001907108, 1907108, LXEO, edgar:1907108

Also known as LEXEO THERAPEUTICS, INC., Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation